Thrivent Financial for Lutherans Increases Stock Position in Globus Medical, Inc. $GMED

Thrivent Financial for Lutherans increased its position in Globus Medical, Inc. (NYSE:GMED) by 25.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 65,562 shares of the medical device company’s stock after acquiring an additional 13,455 shares during the period. Thrivent Financial for Lutherans’ holdings in Globus Medical were worth $5,725,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. raised its holdings in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the last quarter. Advisory Services Network LLC purchased a new position in Globus Medical in the 3rd quarter worth approximately $26,000. EverSource Wealth Advisors LLC raised its stake in Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the last quarter. Parallel Advisors LLC raised its stake in Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Globus Medical during the 3rd quarter valued at $36,000. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. TD Cowen upgraded shares of Globus Medical to a “strong-buy” rating in a research note on Tuesday, January 27th. Barclays boosted their target price on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Needham & Company LLC boosted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wells Fargo & Company decreased their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.36.

Globus Medical Price Performance

Shares of GMED stock opened at $84.46 on Friday. Globus Medical, Inc. has a 1 year low of $51.79 and a 1 year high of $101.40. The firm has a fifty day moving average price of $87.31 and a 200-day moving average price of $87.83. The company has a market cap of $11.46 billion, a price-to-earnings ratio of 19.64, a PEG ratio of 1.73 and a beta of 1.00.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same quarter in the previous year, the firm posted $0.68 EPS. The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Equities research analysts expect that Globus Medical, Inc. will post 4.74 EPS for the current year.

Insider Activity

In other news, EVP Kelly Huller sold 20,000 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 18.38% of the stock is currently owned by insiders.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.